Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) has announced the schedule for a conference call for investors and analysts to discuss the Un-audited Financial Results for the third quarter and nine months of the fiscal year 2026. The conference call is scheduled to take place on Thursday, February 12, 2026, at 06:15 p.m. IST. The senior management of the company will participate in the call, which will commence with a management discussion on the Q3 & 9MFY26 results to be declared earlier in the day, followed by an interactive Question & Answer session. Details for the conference call include primary dial-in numbers (+91 22 6280 1141 / +91 22 7115 8042) and international toll-free numbers for Singapore, Hong Kong, USA, and UK. Participants are encouraged to pre-register via a provided link to receive dial-in numbers, a passcode, and a PIN via email. Attendees are advised to dial in 5-10 minutes prior to the scheduled start time. For further information, investors can contact Kundan Kumar Jha (Company Secretary) at Cohance Lifesciences Limited, or Cyndrella Carvalho (Head - Investor Relations), or Gavin Desa / Rishab Barar at CDR India.
